|Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.)||CEO & Exec. Director||417.79k||N/A||1983|
|Mr. Andrew Taylor B.Com., C.A.||Chief Financial Officer||N/A||N/A||N/A|
|Prof. Sue Fletcher||Chief Scientific Officer||N/A||N/A||N/A|
|Dr. May Orfali M.B.A., M.D.||Chief Medical Officer of US Operations||N/A||N/A||1968|
|Dr. Glenn Noronha||Chief Devel. Officer||N/A||N/A||1965|
|Mr. Kevin Ronald Hart B.Com, B.Comm (Hons), C.A., F.C.A., FCA||Company Sec.||N/A||N/A||1962|
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and PYC-001, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for kidney, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders, including Motor Neurone Disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
PYC Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.